Literature DB >> 26829991

Incidence of West Nile virus infection in the Dallas-Fort Worth metropolitan area during the 2012 epidemic.

P C Williamson1, B Custer2, B J Biggerstaff3, R S Lanciotti3, M H Sayers4, S J Eason4, M R Dixon5, V Winkelman1, M C Lanteri2, L R Petersen3, M P Busch2.   

Abstract

The 2012 West Nile virus (WNV) epidemic was the largest since 2003 and the North Texas region was the most heavily impacted. We conducted a serosurvey of blood donors from four counties in the Dallas-Fort Worth area to characterize the epidemic. Blood donor specimens collected in November 2012 were tested for WNV-specific antibodies. Donors positive for WNV-specific IgG, IgM, and neutralizing antibodies were considered to have been infected in 2012. This number was adjusted using a multi-step process that accounted for timing of IgM seroreversion determined from previous longitudinal studies of WNV-infected donors. Of 4971 donations screened, 139 (2·8%) were confirmed WNV IgG positive, and 69 (1·4%) had IgM indicating infection in 2012. After adjusting for timing of sampling and potential seroreversion, we estimated that 1·8% [95% confidence interval (CI) 1·5-2·2] of the adult population in the Dallas-Fort Worth area were infected during 2012. The resulting overall estimate for the ratio of infections to reported WNV neuroinvasive disease (WNND) cases was 238:1 (95% CI 192-290), with significantly increased risk of WNND in older age groups. These findings were very similar to previous estimates of infections per WNND case, indicating no change in virulence as WNV evolved into an endemic infection in the United States.

Entities:  

Keywords:  Blood transfusion-associated infections; West Nile virus; incidence

Mesh:

Substances:

Year:  2016        PMID: 26829991      PMCID: PMC9148807          DOI: 10.1017/S0950268816000042

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  21 in total

1.  Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection.

Authors:  G Tardei; S Ruta; V Chitu; C Rossi; T F Tsai; C Cernescu
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  West Nile fever characteristics among viremic persons identified through blood donor screening.

Authors:  Shimian Zou; Gregory A Foster; Roger Y Dodd; Lyle R Petersen; Susan L Stramer
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

3.  West Nile virus nucleic acid persistence in whole blood months after clearance in plasma: implication for transfusion and transplantation safety.

Authors:  Marion C Lanteri; Tzong-Hae Lee; Li Wen; Zhanna Kaidarova; Marjorie D Bravo; Nancy E Kiely; Hany T Kamel; Leslie H Tobler; Philip J Norris; Michael P Busch
Journal:  Transfusion       Date:  2014-06-26       Impact factor: 3.157

Review 4.  Approximate interval estimation of the ratio of binomial parameters: a review and corrections for skewness.

Authors:  J J Gart; J Nam
Journal:  Biometrics       Date:  1988-06       Impact factor: 2.571

5.  Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors.

Authors:  Harry E Prince; Leslie H Tobler; Mary Lapé-Nixon; Gregory A Foster; Susan L Stramer; Michael P Busch
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

6.  Performance of immunoglobulin G (IgG) and IgM enzyme-linked immunosorbent assays using a West Nile virus recombinant antigen (preM/E) for detection of West Nile virus- and other flavivirus-specific antibodies.

Authors:  Wayne R Hogrefe; Ronald Moore; Mary Lape-Nixon; Michael Wagner; Harry E Prince
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

7.  Unifying the spatial epidemiology and molecular evolution of emerging epidemics.

Authors:  Oliver G Pybus; Marc A Suchard; Philippe Lemey; Flavien J Bernardin; Andrew Rambaut; Forrest W Crawford; Rebecca R Gray; Nimalan Arinaminpathy; Susan L Stramer; Michael P Busch; Eric L Delwart
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

8.  West Nile virus epidemic, northeast Ohio, 2002.

Authors:  Anna M Mandalakas; Christopher Kippes; Joseph Sedransk; Jeffrey R Kile; Asha Garg; John McLeod; Richard L Berry; Anthony A Marfin
Journal:  Emerg Infect Dis       Date:  2005-11       Impact factor: 6.883

9.  Evolutionary dynamics of West Nile virus in the United States, 1999-2011: phylogeny, selection pressure and evolutionary time-scale analysis.

Authors:  Germán Añez; Andriyan Grinev; Caren Chancey; Christopher Ball; Namita Akolkar; Kevin J Land; Valerie Winkelman; Susan L Stramer; Laura D Kramer; Maria Rios
Journal:  PLoS Negl Trop Dis       Date:  2013-05-30

10.  Continued evolution of West Nile virus, Houston, Texas, USA, 2002-2012.

Authors:  Brian R Mann; Allison R McMullen; Daniele M Swetnam; Vence Salvato; Martin Reyna; Hilda Guzman; Rudy Bueno; James A Dennett; Robert B Tesh; Alan D T Barrett
Journal:  Emerg Infect Dis       Date:  2013       Impact factor: 6.883

View more
  3 in total

1.  The Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan.

Authors:  Cassandra D Josephson; Simone Glynn; Sunitha Mathew; Rebecca Birch; Sonia Bakkour; Lisa Baumann Kreuziger; Michael P Busch; Kathleen Chapman; Carla Dinardo; Jeanne Hendrickson; Eldad A Hod; Shannon Kelly; Naomi Luban; Alan Mast; Philip Norris; Brian Custer; Ester Sabino; Bruce Sachais; Bryan R Spencer; Mars Stone; Steve Kleinman
Journal:  Transfusion       Date:  2022-04-19       Impact factor: 3.337

Review 2.  Age-related alterations in immune responses to West Nile virus infection.

Authors:  R R Montgomery
Journal:  Clin Exp Immunol       Date:  2016-10-17       Impact factor: 4.330

3.  Cumulative Incidence of West Nile Virus Infection, Continental United States, 1999-2016.

Authors:  Shannon E Ronca; Kristy O Murray; Melissa S Nolan
Journal:  Emerg Infect Dis       Date:  2019-02       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.